Core Viewpoint - Sanara MedTech Inc. is set to report its third quarter 2025 financial results on November 12, 2025, before U.S. markets open, indicating ongoing transparency and communication with investors [1]. Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skin markets [4]. - The company markets and distributes a range of surgical, wound, and skin products primarily in the North American advanced wound care and surgical tissue repair markets [4]. - Key products include CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft, and various advanced biologic products [4]. - Sanara's pipeline includes product candidates targeting opportunistic pathogens, wound healing, and necrotic tissue debridement, showcasing its commitment to innovation [4]. Upcoming Events - A conference call and webcast will be held on November 12, 2025, at 8:00 a.m. Eastern Time to discuss the financial results and engage in a Q&A session [2]. - The conference call can be accessed via a toll-free number, with a replay available until November 26, 2025 [2]. Investor Relations - Investor relations contacts are provided for further inquiries, indicating the company's openness to communication with stakeholders [7].

Core Viewpoint - Sanara MedTech Inc. has appointed Seth Yon as President and Chief Executive Officer, effective September 15, 2025, succeeding Ron Nixon, who will remain as Executive Chairman [1][2]. Leadership Transition - The Board of Directors unanimously voted to appoint Seth Yon, highlighting his strategic leadership and proven track record over the past seven years, during which Sanara achieved a compounded annual net revenue growth of 53% over the last three fiscal years [2]. - Ron Nixon emphasized that this transition is part of a long-term initiative to strengthen the senior leadership team for future success in the market [2]. Seth Yon's Background - Seth Yon joined Sanara in March 2018 and has held various senior management roles, including Director of Sales, National Sales Director, and President of Commercial, before becoming President and Chief Commercial Officer [2][3]. - His experience includes leading the development of sales processes and metrics, contributing to significant growth in the Sanara Surgical segment [2]. Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative medical technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skin markets [4][5]. - The company markets a range of products, including CellerateRX Surgical Activated Collagen and various advanced biologic products, primarily in the North American advanced wound care and surgical tissue repair markets [4][5].

Core Viewpoint - Sanara MedTech Inc. is set to report its second quarter 2025 financial results on August 13, 2025, focusing on transformative technologies in the medical field to enhance clinical outcomes and reduce healthcare costs [1][4]. Financial Results Announcement - The financial results for the quarter ending June 30, 2025, will be discussed in a conference call and webcast scheduled for August 13, 2025, at 8:00 a.m. Eastern Time [2]. - A toll-free number for the teleconference is provided, along with details for international callers and a replay option available until August 27, 2025 [2]. Company Overview - Sanara MedTech Inc. specializes in developing and commercializing technologies aimed at improving clinical outcomes in surgical, chronic wound, and skin markets [4]. - The company markets a range of products including CellerateRX Surgical Activated Collagen and FORTIFY TRG Tissue Repair Graft, primarily in the North American advanced wound care and surgical tissue repair markets [4]. - Sanara's product pipeline includes innovative candidates targeting opportunistic pathogens, wound healing, and tissue debridement, with a commitment to meeting quality and regulatory standards [4].

Core Insights - Sanara MedTech Inc. has launched a pilot program through its subsidiary Tissue Health Plus (THP) aimed at providing value-based wound care solutions for chronic wounds across six states [1][2] - The THP technology platform will serve as a Wound Care Operating System for a provider group, utilizing Co-Pilot software to standardize patient care and streamline administrative processes [2] - The pilot program is expected to validate and optimize the THP technology platform through real-world patient encounters, with plans for expansion to additional practitioners and locations [2] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing technologies to improve clinical outcomes and reduce healthcare costs in surgical and chronic wound markets [4] - The company markets a range of surgical and wound care products primarily in the North American market, including CellerateRX Surgical Activated Collagen and various antimicrobial solutions [4][5] - THP aims to transform the $100+ billion wound care market by addressing gaps in chronic wound care, with a goal of improving healing rates to over 85% and reducing total care costs by more than 25% [3] Technology and Innovation - THP's platform combines AI-powered clinical decision support, virtual care coordination, and an integrated provider network to deliver personalized wound care [3] - The pilot program is part of a broader strategy to engage with payers and financial partners to support the implementation of THP's value-based care solutions [2][3]